It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

LivaNova plc (LIVN) Ord GBP1 (DI)

Sell:$84.01 Buy:$84.07 Change: $1.82 (2.21%)
Market closed |  Prices as at close on 21 June 2021 | Switch to live prices |
Change: $1.82 (2.21%)
Market closed |  Prices as at close on 21 June 2021 | Switch to live prices |
Change: $1.82 (2.21%)
Market closed |  Prices as at close on 21 June 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

LivaNova PLC is a medical device company. The Company is focused on the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The Company operates through two segments: Cardiac Surgery and Neuromodulation. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.

Contact details

20 Eastbourne Terrace
W2 6LG
United Kingdom
+44 (20) 33250662

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$4.02 billion
Shares in issue:
48.86 million
Health Care Equipment
Great Britain
US dollar

Key personnel

  • Daniel Moore
    Independent Chairman of the Board
  • Damien McDonald
    Chief Executive Officer, Director
  • Alex Shvartsburg
    Interim Chief Financial Officer
  • Trui Hebbelinck
    Chief Human Resource Officer
  • Keyna Skeffington
    Senior Vice President, General Counsel and Company Secretary
  • Marco Dolci
    Head of Global Operations and R&D

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.